Date:	--/--/-- --:--:--
Event Id:	E5DAXA1HX
Action Type:	ACQUISITION
Action Status:	ANNOUNCED
Acquirer Symbol:
Target Symbol:	VIGL
Updated:	--/--/-- --:--:--
Purchase Price Per Share:	8
Price Per Share Currency:	USD
News References:	https://www.sec.gov/Archives/edgar/data/1827087/000119312525151902/d928340ddefm14a.htm

Action Notes

Sanofi announced today that it has entered into an agreement to acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases. This acquisition in neurology, one of Sanofi's four strategic disease areas, enhances Sanofi's early-stage pipeline and includes VG-3927, which will be evaluated in a phase 2 clinical study in Alzheimer's disease. VG-3927 is an oral small molecule TREM2 agonist. Activating TREM2 is expected to enhance the neuroprotective function of microglia in Alzheimer's disease. The Vigil special shareholder meeting to vote on the transaction will be held on 08/04.